FDA Approves Axsome Therapeutics’ Symbravo for Migraine with or without Aura Posted on February 1, 2025February 1, 2025 by admin Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 hours, and reduces the need for rescue medication.